UNSPSC 51321711: Atorvastatin magnesium trihydrate

This classification denotes a hmg-coa reductase inhibitor 2C33H34FN2O5.Mg.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S40X654V9C, chemically known as magnesium, bis((.beta.r,.delta.r)-2-(4-fluorophenyl)-.beta.-(hydroxy-.kappa.o)-.delta.-hydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoato-.kappa.o1)-, hydrate (1:3), (t-4)-, but more generally known as atorvastatin magnesium trihydrate, which bears US NIH Compound Identifier 24849182.

UNSPSC 51321711 Atorvastatin magnesium trihydrate is a Commodity code for a specific pharmaceutical formulation widely used in emergency medical and pharmacy benefit contexts. State and local governments procure this drug and related medications primarily through fire rescue services, health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Recent solicitations show that purchases occur both as individual line items within broader advanced life support medication contracts and as part of larger generic pharmaceutical catalogs distributed through state and regional cooperative vehicles. Issuing bodies include municipal fire departments, state health agencies, and multistate purchasing cooperatives that consolidate procurement across dozens of participating jurisdictions. The work itself involves supply chain fulfillment with strict compliance requirements — expiration-date management, cold-chain logistics where required, Safety Data Sheets (SDSs) under OSHA standards, FDA manufacturing-practice certification, and Drug Supply Chain Security Act (DSCSA) compliance.

Geographic activity centers on Texas, Minnesota, and Florida, with multistate cooperative purchasing agreements extending reach to Oregon and other member jurisdictions. The City of Tampa Fire Rescue issued IFB 26P00188 in April 2026 for Advanced Life Support Medications including multiple specific formulations, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the award carried a Small Local Business Enterprise (SLBE) sheltered market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 in January 2026 for Generic Multi Source Pharmaceuticals and OTC Products, due March 26, 2026, requiring vendors to distribute products through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) with contract effectiveness set for July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to explore direct-to-manufacturer prescription programs, signaling potential future formal solicitations beyond traditional cooperative-purchasing and pharmacy-benefit-manager channels.